Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06055608 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary endpoints: details revised at 1 of 1 entryStudy sites: 20 to 21 · Eligibility criteria expanded, about 34 wordsShow 2 more changesShow less
Study sites: 20 to 21
Eligibility criteria expanded, about 34 words
MinorSite contacts updated at 1 of 20 sitesv22
MinorSite contacts updated at 1 of 20 sitesv21
MinorSite contacts updated at 2 of 20 sitesv20
MinorEligibility criteria expanded, about 74 wordsSecondary endpoints: details revised at 8 of 8 entries · Site contacts updated at 2 of 20 sitesv19Show 2 more changesShow less
Secondary endpoints: details revised at 8 of 8 entries
MinorStart date changed from estimate of May 24, 2024 to May 22, 2024v6
MinorStudy sites: 18 to 20Start date: Apr 30, 2024 to May 24, 2024v5Show 1 more changeShow less
Start date: Apr 30, 2024 to May 24, 2024
NotableTrial status: Not Yet Recruiting to RecruitingStart date: Feb 21, 2024 to Apr 30, 2024 · Eligibility criteria expanded, about 31 words · Study sites revised (18)v4Show 3 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.